Cardiotoxicity associated with the use of trastuzumab in breast cancer patients

Expert Review of Anticancer Therapy

Volumn 7, Issue 12, 2007, Pages 1763-1771

  Perik, Patrick J ^a   de Korte, Maarten Alexander ^a   van Veldhuisen, Dirk J ^a   Gietema, Jourik A ^a   Sleijfer, Dirk T ^a   de Vries, Elisabeth G E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Breast cancer; Cardiotoxicity; HER2; Trastuzumab

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ANTHRACYCLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCETAXEL; DOXORUBICIN; ENALAPRIL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; INDIUM 111; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; PENTETIC ACID; PLACEBO; PROPRANOLOL; RAZOXANE; TRASTUZUMAB;

ADD ON THERAPY; BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DRUG RESPONSE; DRUG USE; DRUG WITHDRAWAL; HEART DISEASE; HEART FAILURE; HUMAN; LOADING DRUG DOSE; METASTASIS; MULTIPLE CYCLE TREATMENT; NONHUMAN; PATHOPHYSIOLOGY; PATIENT MONITORING; REVIEW; SYSTEMIC THERAPY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HEART DISEASES; HUMANS; INCIDENCE; MONITORING, PHYSIOLOGIC; RISK FACTORS;

EID: 37349063756     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.12.1763     Document Type: Review

References (63)

1. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182 (1987).
2. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001).
3. Marty M, Cognetti F, Maraninchi D et al. Randomized Phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J. Clin. Oncol, 23, 4265-4274 (2005).
4. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzurnab for breast cancer. N. Engl. J. Med. 354, 809-820(2006).
5. Piccart-Gebhatt MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. EngL J. Med. 353, 1659-1672(2005).
6. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. I Med. 353, 1673-1684 (2005).
7. Slamon D, Eiermann W, Robert N. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Proc. San Antonio Breast Cancer Symposium (2005) (Abstract 1).
8. Hudis CA. Trastuzumab - mechanism of action and use in clinical practice. N. Engl. J Med. 357,39-51 (2007).
9. Baselga J. Safety profile of Herceptin as a single agent and in combination with chemotherapy. Eur. J Cancer 35, S324 (1999).
10. Smith I, Procter M, Gelber RD et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369, 29-36 (2007).
11. Suter TM, Procter M, van Veldhuisen DJ et al. Trastuzumab-associated cardiac adverse effects in the Herceptin Adjuvant Trial. J. Clin. Oncol. 25(25), 3859-3865 (2007).
12. Rastogi P, Jeong J, Geyer CE et al. Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of subsequential doxorubicin/cyclophosphamide (AC) followed by paclitaxel (T) vs. AC followed by T with trastuzumab (H). J. Clin. Oncol. 25, LBA513 (2007) (Abstract).
13. Tan-Chiu E, Yothers G, Romond E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J. Clin. Oncol. 23, 7811-7819 (2005).
14. Chien KR. Herceptin and the heart - a molecular modifier of cardiac failure. N. Engl. J. Med. 354, 789-790 (2006).
15. Guarneri V, Lendian DJ, Valero V et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J. Clin. Oncol. 24, 4107-4115 (2006).
16. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N. Engl. J. Med. 339, 900-905 (1998).
17. Sawyer DB, Zuppinger C, Miller TA, Eppenberger HM, Suter TM. Modulation of andisacycline-induced myofibfillar disarray in rat ventricular myocytes by neuregulin-1β and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 105, 1551-1554 (2002).
18. Pentassuglia L, Timolati F, Seifriz F et al. Inhibition of ErbB2/ neuregulin signaling augments paditaxel-induced cardiotoxicity in adult ventricular myocytes. Exp. Cell Res. 313, 1588-1601 (2007).
19. Kuramochi Y, Cote GM, Guo X et al. Cardiac enclothelial cells regulate reactive oxygen species-induced cardiomyocyte apoptosis through neuregulin-1β/erbB4 signaling. J. Biol Cbem. 279, 51141-51147 (2004).
20. Ewer MS, Vooletich MT, Durand JB et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J. Clin. Oncol. 23, 7820-7826 (2005).
21. Lee KF, Simon H, Chen H et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378, 394-398 (1995).
22. Crone SA, Zhao YY, Fan L et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat. Med. 8, 459-465 (2002).
23. Ozcelik C, Erdmann B, Pilz B et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc. Natl Acad. Sci. USA 99, 8880-8885 (2002).
24. Fuchs IB, Landt S, Bueler H et al. Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin). Breast Cancer Res. Treat. 82, 23-28 (2003).
25. Uray IP Connelly JH, Thomazy V et al. Left ventricular unloading alters receptor tyrosine kinase expression in the failing human heart. J. Heart Lung Transplant 21, 771-782 (2002).
26. 111 In-DTPA-trastuzumab. Br. J. Pharmacol. 143, 99-106 (2004).
27. Perik PJ, Lub-De Hooge MN, Gietema JA et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J. Clin. Oncol. 24, 2276-2282 (2006).
28. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur. J. Cancer 43, 2046-2051 (2007).
29. Ewer MS. The anthracycline-trastuzumab interaction: up-regulated binding may provide vital mechanistic insight. Eur. J. Cancer 43, 2024-2025 (2007).
30. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97, 2869-2879 (2003).
31. Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J. Clin. Oncol. 25, 3808-3815 (2007).
32. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J. Clin. Oncol. 23, 2900-2902 (2005).
33. Slamon D. Data from the BCIRG 006 study. Presented at: Karnofsky Memorial Award and Lecture, ASCO 2006. Atlanta, GA, USA June 2-6 (2006)
34. Geyer CE, Bryant JL, Romond EH et al. Update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/ cyclophosphamide (AC) followed by paclitaxel (T) vs. AC followed by T with trastuzumab (H). Proc. Am. Soc. Clin. Oncol. (2006) (Abstract 581).
35. Halyard MY, Pisansky TM, Solin LJ et al. Adjuvant radiotherapy (RT) and trastuzumab in stage I-IIA breast cancer. toxicity data from North Central Cancer Treatment Group Phase III trial N9831. Proc. Am. Soc. Clin. Oncol. (2006) (Abstract 523).
36. Mason JW, Bristow MR, Billingham ME, Daniels JR. Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat. Rep. 62, 857-864 (1978).
37. Marchandise B, Schroeder E, Bosly A et al. Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am. Heart J. 118, 92-98 (1989).
38. Ewer MS, Ali MK, Gibbs HR et al. Cardiac diastolic function in pediatric patients receiving doxorubicin. Acta Oncol. 33, 645-649 (1994).
39. Reutelingsperger CP. Dumont E, Thimister PW et al. Visualization of cell death in vivo with the annexin A5 imaging protocol. J. Immunol. Methods 265, 123-132 (2002).
40. Estorch M, Carrio I. Martinez-Duncker D et al. Myocyte cell damage after administration of doxorubicin or mitoxantrone in breast cancer patients assessed by indium 111 antimyosin monoclonal antibody studies. J. Clin. Oncol. 11, 1264-1268 (1993).
41. Valdés Olmos RA, Bokkel Huinink WW, Dewit LG et al. Iodine- 123 metaiodobenzylguanidine in the assessment of late cardiac effects from cancer therapy. Eur. J. Nucl Med. 23, 453-458 (1996).
42. Behr TM, Behe M, Wormann B. Trastuzumab and breast cancer. N. Engl. J. Med. 345, 995-996 (2001).
43. Cardinale D, Sandri MT, Colombo A et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109, 2749-2754 (2004).
44. Meinardi MT, van Veldhuisen DJ, Gietema JA et al. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J. Clin. Oncol. 19, 2746-2753 (2001).
45. Perik PJ, De Vries EG, Boomsma F et al. Use of natriuretic peptides for detecting cardiac dysfunction in long-term disease-free breast cancer survivors. Anticancer Res. 25, 3651-3657 (2005).
46. Jensen BY, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann. Oncol. 13, 699-709 (2002).
47. Konstam MA, Rousseau MF, Kronenberg MW et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation 86, 431-438 (1992).
48. Jensen BV, Nielsen SL, Skovsgaard T. Tieatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy. Lancet 347, 297-299 (1996).
49. Silber JH, Cnaan A, Clark BJ et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J. Clin. Oncol. 22, 820-828 (2004).
50. Cardinale D, Colombo A, Sandri MT et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114, 2474-2481 (2006).
51. Fu LX, Bergh CH, Hoebeke J et al. Effect of metoprolol on activity of β-adrenoceptor coupled to guanine nucleotide binding regulatory proteins in adriamycin-induced cardiotoxicity. Basic Res. Cardiol. 86, 117-126 (1991).
52. Mak IT, Weglicki WB. Protection by β-blocking agents against free radical-mediated sarcolemmal lipid peroxidation. Circ. Res. 63, 262-266 (1988).
53. Oliveira PJ, Bjork JA, Santos MS et al. Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. Toxicol Appl. Pharmacol. 200, 159-168 (2004).
54. Noori A, Lindenfeld J, Wolfel E et al. β-blockade in adriamycin-induced cardiomyopathy. J. Card. Fail. 6, 115-119 (2000).
55. Hunt SA, Abraham WT, Chin MH et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation an d Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Cirrulation 112, e154-e235 (2005)
56. Chia S, Clemons M, Martin LA et al. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter Phase II trial. J. Clin. Oncol. 24, 2773-2778 (2006).
57. Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J. Clin. Oncol. 25, 3525-3533 (2007).
58. Milano GA, Lescaut W, Formento JL et al. HER2 genetic polymorphism and pharmacodynamics of trastuzumab-based treatment in breast cancer patients. Proc. Am. Soc. Clin. Oncol. (2007) (Abstract No. 501).
59. Muss HB, Thor AD, Berry DA et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N. Engl. J. Med. 330, 1260-1266 (1994).
60. Hensley ML, Schuchter LM, Lindley C et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J. Clin. Oncol. 17, 3333-3355 (1999).
61. Swain SM, Whaley FS, Gerber MC et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J. Clin. Oncol. 15, 1318-1332 (1997).
62. Timolati F, Ott D, Pentassuglia L et al. Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes. J. Mol. Cell. Cardiol. 41, 845-854 (2006).
63. Weinstein EJ, Leder P. The extracellular region of heregulin is sufficient to promote mammary gland proliferation and tumorigenesis but not apoptosis. Cancer Res. 60, 3856-3861 (2000).